Medicamen Biotech's Q4 FY 2025-26 Quarterly Results

Result Summary

• Medicamen Biotech Ltd reported a 31.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 79.0%.
• Its expenses for the quarter were up by 26.5% QoQ and 77.2% YoY.
• The net profit increased 171.3% QoQ and increased 138.0% YoY.
• The earnings per share (EPS) of Medicamen Biotech Ltd stood at 3.28 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Medicamen Biotech Ltd is a pharmaceutical company that operates in the biotechnology and healthcare industry. The company specializes in the production and distribution of pharmaceutical products, with a focus on both domestic and international markets. Recent major developments for Medicamen Biotech Ltd include the expansion of its production facilities and the introduction of new pharmaceutical products aimed at addressing emerging healthcare needs. As a player in the biotechnology sector, the company is engaged in research and development activities to innovate and improve its product offerings. However, specific details about recent product launches or strategic partnerships are not available from the current data.

Revenue

In the fourth quarter of fiscal year 2026 (Q4FY26), Medicamen Biotech Ltd reported a total income of ₹62.38 crores. This represents a substantial increase from the previous quarter (Q3FY26), where the total income was ₹47.44 crores, reflecting a quarter-over-quarter (QoQ) growth of 31.5%. Compared to the same quarter in the previous fiscal year (Q4FY25), the total income increased from ₹34.84 crores, resulting in a year-over-year (YoY) growth of 79.0%. These figures highlight the company's ability to generate higher revenue over time, although the specific drivers of this revenue growth are not detailed in the provided data.

Profitability

The profitability of Medicamen Biotech Ltd in Q4FY26 shows significant improvement. The company's profit before tax was ₹5.06 crores, up from ₹2.11 crores in Q3FY26—a QoQ increase of 139.8%. Compared to Q4FY25, where the profit before tax was ₹2.49 crores, the YoY increase is 103.2%. After accounting for taxes, the profit after tax stands at ₹4.45 crores for Q4FY26, marking a substantial rise from ₹1.64 crores in Q3FY26 and ₹1.87 crores in Q4FY25, with QoQ and YoY increases of 171.3% and 138.0%, respectively. Earnings per share (EPS) also saw significant growth, rising to ₹3.28 in Q4FY26 from ₹1.21 in Q3FY26 and ₹1.47 in Q4FY25, depicting QoQ and YoY increases of 171.1% and 123.1%, respectively.

Operating Metrics

The total expenses for Medicamen Biotech Ltd in Q4FY26 amounted to ₹57.32 crores, compared to ₹45.33 crores in Q3FY26 and ₹32.35 crores in Q4FY25. This indicates a QoQ increase of 26.5% and a YoY increase of 77.2%. The tax expense for Q4FY26 was ₹0.61 crores, slightly higher than the ₹0.48 crores in Q3FY26 but slightly less than the ₹0.63 crores in Q4FY25. The QoQ change in tax expense was 27.1%, while the YoY change was -3.2%. These operational metrics reflect changes in the company's cost structure over the quarters and the year. The data provided does not include additional operating metrics such as debt-to-equity ratio or current ratio, and thus these ratios could not be calculated.